Answer
Yes, mavacamten is contraindicated with clarithromycin, a strong CYP3A4 inhibitor, in CYP2C19 poor metabolisers.
Sources for this answer
- Mavacamten BMS 2.5 mg, 5 mg, 10 mg, 15 mg hard capsulesBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 6Document updated
Sources checked